Yes, Ozempic is legal in Europe. The European Medicines Agency granted it marketing authorization on February 8, 2018, making it available across all EU member states. However, it is approved only for type 2 diabetes, it requires a prescription, and the rules around how it can be used and paid for vary significantly from country to country.
What Ozempic Is Approved For in the EU
Ozempic is authorized in the EU for treating adults with insufficiently controlled type 2 diabetes alongside diet and exercise. It can be prescribed on its own when the first-line diabetes drug metformin isn’t suitable, or it can be added to other diabetes medications. That’s the full scope of its legal indication in Europe.
Notably, Ozempic is not approved for weight loss in the EU. If you’re looking for the version of semaglutide (the same active ingredient) that is legally approved for weight management, that product is called Wegovy. It was approved separately by the EMA for adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related health condition such as high blood pressure, high cholesterol, or prediabetes. Wegovy is also approved for adolescents aged 12 and older with obesity who weigh more than 60 kg. The two products contain the same molecule at different doses and have different legal classifications, so the distinction matters.
Prescription Requirements Across Europe
Ozempic is classified as a prescription-only medicine throughout the EU. You cannot legally buy it over the counter in any member state. The EMA has been explicit that all GLP-1 receptor agonists, the drug class Ozempic belongs to, should only be used under medical supervision. Purchasing these drugs without a prescription is strongly discouraged by regulators, both for safety reasons and because of ongoing supply concerns for diabetes patients who depend on them.
The UK After Brexit
Since the UK left the EU, medicines there are regulated by the MHRA rather than the EMA. Ozempic is approved in the UK with the same indication: type 2 diabetes in adults, alongside diet and exercise. The MHRA has gone a step further than general guidance by actively discouraging off-label prescribing of Ozempic for weight loss, stating that existing stock must be conserved for diabetes patients. UK doctors are instructed to prescribe GLP-1 receptor agonists only for their licensed uses.
Off-Label Weight Loss Prescribing
Across Europe, some doctors have prescribed Ozempic off-label for weight loss, contributing to widespread shortages. The EMA has pushed back on this practice. In guidance issued during the shortage, the agency recommended that clinicians stick to authorized uses and avoid off-label prescribing. It specifically stated that these drugs are not approved for “cosmetic weight loss,” meaning weight loss in people who don’t have obesity or who are overweight without any related health problems. The EMA urged doctors to offer lifestyle advice to those patients instead.
Off-label prescribing is not illegal in most European countries. Doctors generally have clinical freedom to prescribe outside approved indications when they judge it appropriate. But regulators have made clear they consider off-label semaglutide prescribing for weight loss a problem, particularly while supply remains tight for diabetes patients.
Who Pays: Reimbursement Varies Widely
Just because Ozempic is legal doesn’t mean your national health system will cover the cost. Reimbursement rules differ dramatically across Europe, and in several major markets, you may end up paying out of pocket.
Germany excludes all “lifestyle drugs,” including anti-obesity medications, from public reimbursement. Italy classifies GLP-1 drugs as non-reimbursed. Spain similarly lists semaglutide among non-reimbursed medicines. France had an early access program for semaglutide that was later withdrawn.
In Central and Eastern Europe, reimbursement for Ozempic as a diabetes treatment often comes with obesity-related conditions attached. Poland reimburses semaglutide only for obese patients with type 2 diabetes. The Czech Republic and Estonia require a BMI above 30 for enhanced reimbursement, while Slovakia sets the bar at a BMI above 35. In the UK, Wegovy (the weight management version) is available through specialist weight management services for patients with a BMI of 35 or above, or 30 to 34.9 with a weight-related health condition, for a maximum treatment period of two years.
Supply Shortages and Export Restrictions
Surging demand has created real supply problems across Europe. Several countries have responded by restricting exports of Ozempic to keep domestic stock available for their own patients. As of early 2024, Austria, France, Greece, and the Czech Republic had all imposed export bans on Ozempic. Germany’s health ministry stated that exports were not a concern for its market, but the issue remains fluid as demand continues to outpace supply.
Counterfeit Pens in the Supply Chain
In October 2023, the EMA issued an alert after falsified Ozempic pens were found at wholesalers in the EU and the UK. The fake pens carried labels in German and were traced back to wholesalers in Austria and Germany. They bore batch numbers and barcodes copied from genuine packs, but when scanned in the EU’s electronic tracking system, the serial numbers showed as inactive, which flagged them as potential fakes.
No evidence emerged that any counterfeit pens reached patients through legal pharmacies, and no harm was reported. The Austrian and German regulators issued compliance violations to the wholesalers involved. The incident underscores why buying Ozempic through unofficial channels, whether online or from unregulated sellers, carries real risk. Legitimate pharmacies with a prescription remain the only safe route.